RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Immunoprecise Antibodies EBIT 2024

Immunoprecise Antibodies EBIT

-13.98 M CAD

Immunoprecise Antibodies Dividend yield

Ticker

IPA

ISIN

CA45257F2008

WKN

A2QJEC

In 2024, Immunoprecise Antibodies's EBIT was -13.98 M CAD, a -51.03% increase from the -28.55 M CAD EBIT recorded in the previous year.

The Immunoprecise Antibodies EBIT history

YEAREBIT (undefined CAD)
2030e-
2029e18.82
2028e9.77
2027e-
2027e2.09
2026e-4.32
2026e-4.96
2025e-9.24
2024e-13.98
2023-28.55
2022-16.24
2021-6.92
2020-4.1
2019-6.23
2018-4.78
2017-1.34
2015-0.01
2014-0.04
2013-0.1
2012-0.08
2011-0.21
2010-0.1
2009-0.27
2008-0.4
2007-0.62
2006-0.24
2005-0.21
2004-0.2
2003-0.31

Immunoprecise Antibodies Aktienanalyse

What does Immunoprecise Antibodies do?

Immunoprecise Antibodies Ltd is a leading company in the development of antibodies and antibody-based solutions for the pharmaceutical and biotech industry. The company was founded in 2015 as a spin-off from the University of Victoria in Canada and has since experienced rapid growth, expanding into other countries such as the USA, Europe, and Asia. The company's unique business model is based on three pillars: providing innovative research services tailored to the needs of the pharmaceutical and biotech industry, offering a broad portfolio of antibody products for research and diagnostics, and developing a pipeline of new therapeutics currently undergoing clinical trials. The core business of Immunoprecise Antibodies Ltd is the manufacturing of antibodies and antibody-based solutions for research and diagnostics. The company offers a range of innovative services, including antibody engineering, production and purification, and characterization. The research services are provided by an experienced team of scientists and experts in the field of antibody research who work closely with customers to meet their specific needs. In addition, the company has a wide range of antibody products available for various applications in research and diagnostics, including protein quantification, immunohistochemistry, cancer antigen detection, influenza diagnostics, and many others. Immunoprecise Antibodies Ltd has also developed a pipeline of new therapeutics, including antibodies against cancer, inflammation, and infectious diseases, which are currently undergoing clinical trials. The company collaborates closely with leading pharmaceutical and biotech companies to advance the latest developments in this field. To enable better focus and specialization, Immunoprecise Antibodies Ltd is divided into six divisions: humanization/antibody engineering, antibody production, antibody characterization, immunohistochemistry, therapeutics development, and process development. These divisions are strategically designed to cover the needs of customers and facilitate an effective supply chain for antibody production and development. Immunoprecise Antibodies Ltd is a young and dynamic company with a strong focus on innovation and customer satisfaction. It has earned an excellent reputation in the industry and is regarded as a valuable partner for antibody research and development by leading pharmaceutical and biotech companies. The company's goal is to remain a key player in the field of antibody research and continue developing innovative solutions for the pharmaceutical and biotech industry. Immunoprecise Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Immunoprecise Antibodies's EBIT

Immunoprecise Antibodies's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Immunoprecise Antibodies's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Immunoprecise Antibodies's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Immunoprecise Antibodies’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Immunoprecise Antibodies Stock

How much did Immunoprecise Antibodies achieve in EBIT for the current year?

In the current year, Immunoprecise Antibodies has achieved an EBIT of -13.98 M CAD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Immunoprecise Antibodies.

How has the EBIT of Immunoprecise Antibodies developed in recent years?

The EBIT of Immunoprecise Antibodies has increased by -51.03% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Immunoprecise Antibodies?

The EBIT of Immunoprecise Antibodies is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Immunoprecise Antibodies pay?

Over the past 12 months, Immunoprecise Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunoprecise Antibodies is expected to pay a dividend of 0 CAD.

What is the dividend yield of Immunoprecise Antibodies?

The current dividend yield of Immunoprecise Antibodies is .

When does Immunoprecise Antibodies pay dividends?

Immunoprecise Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunoprecise Antibodies?

Immunoprecise Antibodies paid dividends every year for the past 0 years.

What is the dividend of Immunoprecise Antibodies?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunoprecise Antibodies located?

Immunoprecise Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunoprecise Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunoprecise Antibodies from 5/27/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 5/27/2024.

When did Immunoprecise Antibodies pay the last dividend?

The last dividend was paid out on 5/27/2024.

What was the dividend of Immunoprecise Antibodies in the year 2023?

In the year 2023, Immunoprecise Antibodies distributed 0 CAD as dividends.

In which currency does Immunoprecise Antibodies pay out the dividend?

The dividends of Immunoprecise Antibodies are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunoprecise Antibodies

Our stock analysis for Immunoprecise Antibodies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunoprecise Antibodies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.